A Psoriasis Plaque Test on LEO 27989 Ointment and Calcipotriol Plus LEO 27989 Ointment in Patients With Psoriasis Vulgaris

NCT ID: NCT01297166

Last Updated: 2025-02-24

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 25 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-02-28
• Study Completion Date: 2011-04-30

Brief Summary

The purpose of this study is to evaluate the anti-psoriatic effect of LEO 27989 ointment and calcipotriol plus LEO 27989 ointment, using the psoriasis plaque test modified from the method developed by KJ Dumas and JR Scholtz.

Conditions

Psoriasis Vulgaris

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

LEO 27989 ointment

Group Type: EXPERIMENTAL

LEO 27989 ointment

Intervention Type: DRUG

once daily application, 3weeks

Calcipotriol plus LEO 27989 ointment

Intervention Type: DRUG

once daily application, 3weeks

Calcipotriol ointment

Intervention Type: DRUG

once daily application, 3weeks

Vehicle ointment

Intervention Type: DRUG

once daily application, 3weeks

Interventions

LEO 27989 ointment

once daily application, 3weeks

Intervention Type: DRUG

Calcipotriol plus LEO 27989 ointment

once daily application, 3weeks

Intervention Type: DRUG

Calcipotriol ointment

once daily application, 3weeks

Intervention Type: DRUG

Vehicle ointment

once daily application, 3weeks

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Subjects having understood and signed an informed consent form
• Age 18 years or above
• Males, or females of non-child bearing potential
• All skin types
• Subjects with a diagnosis of psoriasis vulgaris with lesions located on arms and/or legs and/or trunk.

Exclusion Criteria

• Male who are not willing to use a local contraception (such as condom) for the entire duration of the study, and refrain from fathering a child within 3 months following the last study drug application
• Females who are pregnant, of child-bearing potential and who wish to become pregnant during the study, or who are breast feeding
• Systemic treatment with biological therapies (marketed or not marketed) with a possible effect on psoriasis vulgaris within 4 weeks (etanercept), 2 months (adalimumab, alefacept, infliximab), 4 months (ustekinumab) or 4 weeks /5 half-lives (which-ever is longer) for experimental biological products prior to randomisation and during the study
• Systemic treatments with all other therapies than biologicals, with a potential effect on psoriasis vulgaris (e.g., corticosteroids, retinoids, immunosuppressants) within the 4-week period prior to randomisation and during the study
• Subjects using one of the following topical drugs for the treatment of psoriasis within the 4 week period prior to randomisation and during the study:

• Potent or very potent (WHO group III-IV) corticosteroids
• PUVA or Grenz ray therapy
• Subjects using one of the following topical drugs for the treatment of psoriasis within two weeks prior to randomisation and during the study:

• WHO group I-II corticosteroids (except if used for treatment of scalp and/or facial psoriasis)
• Topical retinoids
• Vitamin D analogues
• Topical immunomodulators (e.g. macrolides)
• Anthracen derivatives
• Tar
• Salicylic acid
• UVB therapy
• Subjects using emollients on the target plaques within one week before randomisation and during the study
• Initiation of, or expected changes to concomitant medication that may affect psoriasis vulgaris (e.g., beta blockers, anti-malaria drugs, lithium and ACE inhibitors) within 2 weeks prior to the randomisation and during the study
• Subjects with current diagnosis of guttate, erythrodermic, exfoliative or pustular psoriasis
• Subjects with known/suspected disorders of calcium metabolism associated with hypercalcaemia based on medical history
• Subjects with a positive Hepatitis B, Hepatitis C or HIV test
• Subjects who have received treatment with any non-marketed drug substance (i.e., an agent which has not yet been made available for clinical use following registration) within the 4 week period prior to randomisation or longer, if the class of the substance requires a longer washout as defined above (e.g., biological treatments)
• Subjects with current participation in any other interventional clinical, based on interview of the subject
• Subjects with known or suspected hypersensitivity to component(s) of the investigational products
• History of any severe disease or serious current condition (based on subject interview and/or results of screening physical examination) which, in the opinion of the Investigator, would put the subject at risk by participating in the study or would interfere significantly with the evaluation of study results or the study course (e.g. cancer, severe cardiopathy, severe renal insufficiency, severe hepatic insufficiency).
• Subjects with a positive Hepatitis B, Hepatitis C or HIV test
• Subjects with any concomitant medical or dermatological disorder(s) which might preclude accurate evaluation of the psoriasis on the test areas
• Subjects foreseeing an intensive solar exposure during the study (UV radiation, etc.) or having been exposed within two weeks preceding the screening visit
• Subjects with any contraindication to skin biopsy procedures: e.g., allergy to local anaesthetics, topical antiseptics (chlorhexidine), bleeding tendency, treatment with anticoagulant drugs, history of poor wound healing, and history of vasovagal hypotension or syncope.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

LEO Pharma

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Catherine Queille-Roussel, MD

Role: PRINCIPAL_INVESTIGATOR

Centre de Pharmacologie Clinique Applique a la Dermatologie

Locations

CPCAD

Nice, , France

Countries

France

Other Identifiers

2010-022663-35

Identifier Type: -

Identifier Source: secondary_id

PLQ-006

Identifier Type: -

Identifier Source: org_study_id